Skip to main
ALMS
ALMS logo

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc. operates in the promising field of autoimmune disorder treatments with a robust pipeline that includes multiple drug candidates, potentially leading to significant market opportunities. The company projects peak sales of $2 billion for its lead product in systemic lupus erythematosus (SLE) with a conservative 20% probability of FDA approval, reflecting a strong anticipated financial impact if successful. Additionally, positive results from pivotal studies in related indications, such as psoriatic arthritis, suggest a broadening potential for revenue generation beyond just SLE.

Bears say

The negative outlook on Alumis Inc. is largely attributed to several critical risks within its development pipeline, notably related to its leading candidate, ESK-001. These risks encompass the potential inability to advance ESK-001 into pivotal trials punctually, as well as the possibility of the treatment failing to demonstrate significant efficacy in psoriasis (PsO) and systemic lupus erythematosus (SLE). Furthermore, delays in regulatory submissions and approvals in major markets, coupled with strong competition in the immunology and inflammation (I&I) sector, contribute additional uncertainty regarding the company's future market performance and viability.

Alumis Inc (ALMS) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 5 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.